Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
about
Estimating the Effect of Health Insurance on Personal Prescription Drug ImportationA blueprint for pharmacy benefit managers to increase valueCosts and benefits of free medications after myocardial infarction.Medicare Part D--lessons learned and guidance for health-care reform.Drug company-sponsored patient assistance programs: a viable safety net?Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage.The economics of medicines optimization: policy developments, remaining challenges and research priorities.Benefits of statin therapy and compliance in high risk cardiovascular patients.Estimated cost of universal public coverage of prescription drugs in CanadaRacial/ethnic disparities in access to physician care and medications among US stroke survivorsHospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis.Treatment differences by health insurance among outpatients with coronary artery disease: insights from the national cardiovascular data registry.Medication adherence and readmission after myocardial infarction in the Medicare populationCost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UKTicagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysisThe effects of payments for pharmaceuticals: a systematic literature review.Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarctionCost-effectiveness of treating resistant hypertension with an implantable carotid body stimulatorAssessing the impact of drug use on hospital costs.Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patientsRationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial.Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapiesImpact of Physician-Coordinated Intensive Follow-Up on Long-Term Medical Costs in Patients with Unstable Angina Undergoing Percutaneous Coronary Intervention.Underprescription of beneficial medicines in older people: causes, consequences and prevention.Impediments to adherence to post myocardial infarction medications.Patient co-payment and adherence to statins: a review and case studies.Cost-effectiveness of adherence-enhancing interventions: a systematic review.The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis.Action and coping plans related to the behavior of adherence to drug therapy among coronary heart disease outpatients.Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.The association between adherence to cardiovascular medications and healthcare utilization.Incorporating social network effects into cost-effectiveness analysis: a methodological contribution with application to obesity prevention.Purchasing prescription drugs in Canada: hang together or hang separately.Medication adherence after myocardial infarction: a long way left to go.Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America.Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.Non-adherence to cardiovascular medications.β-blocker therapy after acute myocardial infarction.Predictors of adherence to treatment by patients with coronary heart disease after percutaneous coronary intervention.Discharge counseling for patients with heart failure or myocardial infarction: a best practices model developed by members of the American College of Clinical Pharmacy's Cardiology Practice and Research Network based on the Hospital to Home (H2H) In
P2860
Q28272855-B6952F7B-5E4D-43CB-A4F1-575CC85F1E32Q28766235-DA11684B-A6B0-47F1-AEB7-EC659A86E8CEQ33585275-7148E726-C5E2-4821-98EB-A0C11FB01993Q33611440-A94F416E-36DE-466A-AC39-B0B10EA6348BQ33864928-FCAC0C62-76A5-4A44-B839-F9D0820D4743Q34055633-A2604FEF-5653-4D4A-A346-8A613DC8BCC6Q34132415-BBCDFD41-CBEE-4A38-B0DB-5D193920C868Q34187551-DF8FD007-4BB1-4071-ACE5-7171706F4F57Q34467493-F4969CAD-D3B8-49A3-A2BA-A07BDE0F7375Q34536283-15C17537-9972-4B01-9E57-2BE7B29569DCQ34556420-89B974AE-4781-48CE-8608-16F9799EEAA8Q34572760-60B13410-D9DA-435A-9BA8-FC648CBDED09Q35063975-0825BA63-368C-486D-9CFC-4A9535BA96ADQ35675611-55D827BE-14C7-4E31-8C32-457387255590Q36062323-0FAC5F23-6DEA-4CA7-BF33-3713A5822569Q36323515-38339663-8317-4561-9426-F3448058466CQ36469832-A31517BA-B959-4CCB-A3AF-E0028721C3F5Q36949147-35B2EDDA-05E4-4F3C-A4BA-082C4E607623Q37159754-347F87BE-EBB1-49D6-91D4-39D962B1218CQ37187904-A4BD4647-EB8B-4157-A74A-D9C7045C46E0Q37196480-7D37C633-23FF-40ED-9CF7-863529AD87C0Q37229332-F6359805-A84C-4051-A60C-732A8DD932BEQ37719015-0427D99B-D7C6-4B31-932C-D94E2B92DF03Q38014125-6290ECB7-A40C-4D3C-911B-98FA26B701EDQ38068349-8B7EBB3E-9BF9-458A-BDE7-A2AF3530FE23Q38154826-133E7ECA-8362-483E-9535-725233DB08CAQ38687403-9923307F-0CD9-4022-B9CE-10C318451258Q38823423-B2EE544D-70C3-4CCC-AD0F-1A2F56189A7CQ39237737-37EF553C-B9B2-43DA-A834-F5580C2F0438Q40366831-ACE268B2-A1D2-4527-8AC1-7078DF402B29Q40832804-365AFC94-D65E-459C-85A7-B6515EBE3E16Q41829840-8FBF9D04-A702-42E0-B419-C768052B5BEEQ42745017-17200AB9-1C5C-42E0-A38E-CE5CF3D55A35Q43198230-CE14098B-8A06-4758-AB95-4C524DBACC37Q43235282-F93F51B7-8022-453C-A498-C83609F898BAQ43935033-1607CE3F-1704-4AB4-8199-B52DF3CE2BA5Q45230929-CFA2933C-5CD0-4F4B-8E24-D7C62D7F30DEQ46894869-72BCD248-5FCF-46C7-BD31-2DBE6BE4B83CQ47309703-211524E6-6090-40B2-8B1C-B0FD6FA03A74Q50863884-282AC19E-8F06-460B-9C43-D126DF1EBD47
P2860
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of providin ...... rction Medicare beneficiaries.
@en
Cost-effectiveness of providin ...... rction Medicare beneficiaries.
@nl
type
label
Cost-effectiveness of providin ...... rction Medicare beneficiaries.
@en
Cost-effectiveness of providin ...... rction Medicare beneficiaries.
@nl
prefLabel
Cost-effectiveness of providin ...... rction Medicare beneficiaries.
@en
Cost-effectiveness of providin ...... rction Medicare beneficiaries.
@nl
P2093
P2860
P1433
P1476
Cost-effectiveness of providin ...... rction Medicare beneficiaries.
@en
P2093
Amanda R Patrick
Jerry Avorn
Niteesh K Choudhry
William H Shrank
P2860
P304
P356
10.1161/CIRCULATIONAHA.107.735605
P407
P577
2008-02-19T00:00:00Z